Kyn Therapeutics, announced that it is expanding its management team with the appointment of Douglas Carlson as its chief financial officer. Mr. Carlson’s most recent role was vice president, commercial operations, corporate strategy & business development at Collegium Pharmaceutical, a specialty pharmaceutical company focused on pain management. Doug brings nearly two decades of multi-disciplinary experience in the strategic financial management of biotech and healthcare companies. He joins Kyn at a new stage of its growth with the initiation of EP4 antagonist clinical program and the signing of global strategic collaboration with Celgene on two other immuno-oncology programs. Mr. Carlson joined Collegium Pharmaceutical in 2013 and helped oversee the company’s development from a privately-held, clinical-development stage company to a publicly-traded commercial business. At Collegium, Mr. Carlson led corporate strategy, commercial and business development initiatives, including all aspects of strategic decision support and commercial operations.